2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5595 Hypomethylating agents with or without venetoclax in treatment-Naïve Myelodysplastic Syndromes with excess blasts: Subgroup analyses and the role of allogeneic hematopoietic stem cell transplantation

Alex Bataller, MD, PhD, Alexandre Bazinet, MD, MSc2, Ian Bouligny, M.D.3, Guillermo Montalban-Bravo, MD4, Kelly Sharon Chien, MD5, Danielle Hammond, MD6, Nicholas Short, MD7, Ghayas C. Issa, MD8, Tapan Kadia I, MD9, Farhad Ravandi, MD10, Elias Jabbour, MD11, Naval Daver, MD12, Courtney DiNardo, MD, MSCE13, Sanam Loghavi, MD14, Francesco Pesce, MD15, Harold Keer, MD, PhD16, Uday Popat, MD, MBA17, Guillermo Garcia-Manero, MD18
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 Taiho Oncology, Inc., New Jersey, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Biological rationale supports combining venetoclax (Ven) with hypomethylating agents (HMAs) in higher-risk myelodysplastic syndromes (HR-MDS). However, the phase 3, randomized VERONA trial (azacitidine [Aza] ± Ven) failed to demonstrate an overall survival (OS) benefit with the addition of Ven, and debate persists regarding which HR-MDS subgroups, if any, derive meaningful benefit from HMA+Ven. We analyzed outcomes in a large cohort of patients with MDS with excess blasts (MDS-EB) treated with HMA alone versus HMAVen, with particular attention to specific patient subgroups and clinical scenarios.


Methods: This retrospective, single-center study included treatment-naïve patients with MDS-EB (≥5% bone marrow [BM] blasts) diagnosed between 2010 and 2025. Patients were grouped by frontline therapy received, whether administered on-trial or off-trial, as HMA alone or HMAVen. Outcomes were assessed using Kaplan-Meier analysis, Cox regression, and multi-state Markov models.


Results: A total of 358 patients were included: 245 in the HMA cohort and 113 in the HMAVen cohort. Median age was similar between groups (69 vs 70 years, P=ns), while median BM blast percentage was higher in the HMAVen cohort (12% vs 8%, P<0.001). IPSS-R risk distribution was comparable between cohorts, with high-risk disease in 29% of both cohorts and very high-risk disease in 47% vs 60% (P=ns). Mutational profiles were similarly balanced, with the most frequent mutations being TP53 (35% vs 32%), ASXL1 (23% vs 32%), and DNMT3A (17% vs 14%) in the HMA and HMAVen cohorts, respectively. Frontline HMA selection included azacitidine (28% vs 41%, P=ns), decitabine (47% vs 59%, P=ns), and guadecitabine (25% vs 0%, P<0.001) in the HMA and HMAVen cohorts, respectively. Among patients treated with HMAVen, 93% received Ven for 8–14 days, 4% for 1–7 days, and 3% for >15 days during cycle 1.

By IWG 2006 criteria, the overall response rate (ORR) was 62% in the HMA cohort versus 89% in the HMAVen cohort (P<0.001), including comparable complete response rates of 34% and 35%, respectively. By IWG 2023 criteria, the ORR was 51% (HMA) versus 77% (HMAVen) (P<0.001). Rates of allogeneic HSCT were also higher with HMAVen (43% vs 26%, P<0.001).

Median OS and 2-year OS were 19 months/41% with HMA versus 18 months/46% with HMAVen (P=ns), with no OS differences observed across individual HMA types. On univariate subgroup analysis, OS was improved with HMAVen among patients with ASXL1 mutations (ASXL1mut; HR 0.45 [95% CI, 0.24–0.83], P=0.01), IPSS-R very-high risk (HR 0.65 [0.45–0.93], P=0.03), IPSS-M very-high risk (HR 0.65 [0.44–0.96], P=0.03), and BM blasts ≥10% (HR 0.69 [0.49–0.99], P=0.04). Among patients who underwent HSCT, median OS was not reached in either cohort, with 2-year OS of 70% (HMA) and 69% (HMAVen) (P=ns).

On univariate analysis for OS adjusted for HSCT and incorporating a treatment interaction term (variable*ven), the significance of the previously identified associations was attenuated: ASXL1mut (HR 0.59 [0.31–1.11], P=0.09), IPSS-R very-high risk (HR 0.71 [0.50–1.03], P=0.07), IPSS-M very-high risk (HR 0.77 [0.52–1.14], P=0.19), and BM blasts ≥10% (HR 0.81 [0.56–1.16], P=0.25), whereas HSCT remained strongly protective (HR <1, P<0.001). However, the treatment interaction term remained significant for ASXL1mut (HR 0.36 [0.18–0.73], P=0.005), BM blasts ≥10% (HR 0.38 [0.20–0.71], P=0.002), and IPSS-M high (HR 0.31 [0.11–0.90], P=0.031) and very-high risk (HR 0.28 [0.11–0.75], P=0.011). These findings suggest a differential effect of Ven across these subgroups even after adjustment for HSCT.

Markov multistate modeling was designed with three states (treatment, HSCT and death) and 3 possible transitions (treatment to HSCT, treatment to death, and HSCT to death). Compared to HMA, HMAVen significantly increased the hazard of transition from treatment to HSCT (HR 2.39 [1.65-3.46], P<0.001). This trend was also shown in different subgroups: ASXL1mut (HR 2.27 [1.03-5.03], P=0.04) or BM blasts ≥10% (HR 1.84 [1.14-2.99], P=0.012).


Conclusion: Specific MDS-EB subgroups (high-risk disease, ASXL1mut, and BM blasts ≥10%) showed benefit from the addition of Ven to HMA. Ven was associated with an increased rate of transition to HSCT, likely contributing to the observed survival benefit in these subgroups. The persistence of a differential treatment effect after adjustment for HSCT suggests that Ven may also confer benefit independent of facilitating transplant.

Alex Bataller, MD, PhD: No relevant conflicts of interest to declare.